WARP/VWA1 Antibody

WARP expression pattern in the heart.(a) WARP mRNA levels were induced 3 and 7 days after MI. WARP mRNA levels peaked at 7 days after MI and then decreased again at 14 days. (b) Western blot analysis and (c) immunohistochemistry also showed an induction of WARP protein levels in the infarcted LV at 3, 7, and 14 days after MI. Because of different sample-loading, the blots of the 14 days MI were cut and pasted in the same order as the blots of the 3 and 7 days MI. Images of the original unadjusted blots are provided in S1 Fig (d and e) Confocal microscopy confirmed the co-localization of WARP with perlecan in the uninfarcted heart, showing a network of WARP and perlecan as a honeycomb-structure surrounding the cardiomyocytes. In the infarcted LV zones, the WARP-perlecan honeycomb-structure is reduced at 3 days after MI and completely absent at 7 and 14 days after MI and the interaction between WARP and perlecan is disrupted. (e) WARP did not localize on CD45 positive leukocytes or in alpha smooth muscle cells lining the vessels in the remote, border and infarcted zone of the heart 14 days after MI. n≥3; *p≤0.05; **p≤0.005; ***p≤0.001 versus sham, ##p≤0.005; ###p≤0.001 versus remote, bars 1000 μm for (c) and 100 μm for (d) and (e). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0139199), licensed under a CC-BY license. Not internally tested by R&D Systems.

WARP expression pattern in the heart.(a) WARP mRNA levels were induced 3 and 7 days after MI. WARP mRNA levels peaked at 7 days after MI and then decreased again at 14 days. (b) Western blot analysis and (c) immunohistochemistry also showed an induction of WARP protein levels in the infarcted LV at 3, 7, and 14 days after MI. Because of different sample-loading, the blots of the 14 days MI were cut and pasted in the same order as the blots of the 3 and 7 days MI. Images of the original unadjusted blots are provided in S1 Fig (d and e) Confocal microscopy confirmed the co-localization of WARP with perlecan in the uninfarcted heart, showing a network of WARP and perlecan as a honeycomb-structure surrounding the cardiomyocytes. In the infarcted LV zones, the WARP-perlecan honeycomb-structure is reduced at 3 days after MI and completely absent at 7 and 14 days after MI and the interaction between WARP and perlecan is disrupted. (e) WARP did not localize on CD45 positive leukocytes or in alpha smooth muscle cells lining the vessels in the remote, border and infarcted zone of the heart 14 days after MI. n≥3; *p≤0.05; **p≤0.005; ***p≤0.001 versus sham, ##p≤0.005; ###p≤0.001 versus remote, bars 1000 μm for (c) and 100 μm for (d) and (e). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0139199), licensed under a CC-BY license. Not internally tested by R&D Systems.

WARP expression pattern in the heart.(a) WARP mRNA levels were induced 3 and 7 days after MI. WARP mRNA levels peaked at 7 days after MI and then decreased again at 14 days. (b) Western blot analysis and (c) immunohistochemistry also showed an induction of WARP protein levels in the infarcted LV at 3, 7, and 14 days after MI. Because of different sample-loading, the blots of the 14 days MI were cut and pasted in the same order as the blots of the 3 and 7 days MI. Images of the original unadjusted blots are provided in S1 Fig (d and e) Confocal microscopy confirmed the co-localization of WARP with perlecan in the uninfarcted heart, showing a network of WARP and perlecan as a honeycomb-structure surrounding the cardiomyocytes. In the infarcted LV zones, the WARP-perlecan honeycomb-structure is reduced at 3 days after MI and completely absent at 7 and 14 days after MI and the interaction between WARP and perlecan is disrupted. (e) WARP did not localize on CD45 positive leukocytes or in alpha smooth muscle cells lining the vessels in the remote, border and infarcted zone of the heart 14 days after MI. n≥3; *p≤0.05; **p≤0.005; ***p≤0.001 versus sham, ##p≤0.005; ###p≤0.001 versus remote, bars 1000 μm for (c) and 100 μm for (d) and (e). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0139199), licensed under a CC-BY license. Not internally tested by R&D Systems.

WARP expression pattern in the heart.(a) WARP mRNA levels were induced 3 and 7 days after MI. WARP mRNA levels peaked at 7 days after MI and then decreased again at 14 days. (b) Western blot analysis and (c) immunohistochemistry also showed an induction of WARP protein levels in the infarcted LV at 3, 7, and 14 days after MI. Because of different sample-loading, the blots of the 14 days MI were cut and pasted in the same order as the blots of the 3 and 7 days MI. Images of the original unadjusted blots are provided in S1 Fig (d and e) Confocal microscopy confirmed the co-localization of WARP with perlecan in the uninfarcted heart, showing a network of WARP and perlecan as a honeycomb-structure surrounding the cardiomyocytes. In the infarcted LV zones, the WARP-perlecan honeycomb-structure is reduced at 3 days after MI and completely absent at 7 and 14 days after MI and the interaction between WARP and perlecan is disrupted. (e) WARP did not localize on CD45 positive leukocytes or in alpha smooth muscle cells lining the vessels in the remote, border and infarcted zone of the heart 14 days after MI. n≥3; *p≤0.05; **p≤0.005; ***p≤0.001 versus sham, ##p≤0.005; ###p≤0.001 versus remote, bars 1000 μm for (c) and 100 μm for (d) and (e). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0139199), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

WARP/VWA1 Antibody Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse WARP isoform 1
  Arg19-Pro415
  Accession # Q8R2Z5
• Specificity: Detects mouse WARP in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross‑reactivity with recombinant human WARP is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: VWA1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for WARP/VWA1 Antibody

• DKFZp761O051
• von Willebrand factor A domain containing 1
• von Willebrand factor A domain-containing protein 1
• von Willebrand factor A domain-related protein
• VWA1
• WARP

Background

WARP (von Willebrand factor A [vWFA] domain-related protein) is a 50 kDa glycoprotein member of the vWFA domain superfamily of extracellular matrix proteins. It is expressed in embryonic articular cartilage, skeletal muscle and basement membranes in the PNS. WARP forms disulfide-linked homodimers and multimers, and complexes with perlecan. Secreted mouse WARP is 397 amino acids (aa) in length. It contains a vWFA domain (aa 34‑209), and two fibronectin type III domains (aa 211‑394) that likely bind to the GAG modification of perlecan. Cys369 and Cys393 contribute to intermolecular bond formation. There is one alternate start site at Met213. Mature mouse WARP (aa 19‑415) is 93% and 78% aa identical to rat and human WARP, respectively.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for WARP/VWA1 Antibody (AF4927)(2)

Publications using AF4927

• Deckx S, Carai P, Bateman J, Heymans S, Papageorgiou A Breeding Strategy Determines Rupture Incidence in Post-Infarct Healing WARPing Cardiovascular Research. PLoS ONE, 2015-09-25;10(9):e0139199. 2015-09-25 [PMID: 26406320] (IHC, Western Blot, Mouse)
• Stouch A, Zaynagetdinov R, Barham W, Stinnett A, Slaughter J, Yull F, Hoffman H, Blackwell T, Prince L IkappaB kinase activity drives fetal lung macrophage maturation along a non-M1/M2 paradigm. J Immunol, 2014-06-30;193(3):1184-93. 2014-06-30 [PMID: 24981452] (IHC, Mouse)

Bioinformatics

• Gene Symbol: VWA1
• Uniprot:
  • Q8R2Z5()